Understanding the Shift Toward Value-Based Pricing
Global healthcare firms are increasingly turning toward value-oriented models as markets evolve and patient expectations rise. The United States has been at the center of this change, driven by policy updates, payer pressure, and the broader movement toward outcome-driven care. This environment provides practical lessons for organizations worldwide that want to design pricing frameworks aligned with real-world value. The keyword drug pricing reform reflects the urgency and momentum behind this transition.
Why the US Landscape Offers Critical Insights
The US market has undergone notable shifts that highlight the need for pricing strategies rooted in measurable patient outcomes. Payers now expect clearer justification for therapy costs. Providers demand visibility into long-term clinical impact. Patients seek transparency and affordability. These dynamics show how pricing no longer depends solely on R&D investment or market exclusivity. Instead, it reflects the therapeutic value demonstrated across diverse population groups and care settings. Firms outside the US can learn from this progression by prioritizing evidence generation and adopting transparent value narratives.
Aligning Pricing Models With Measurable Outcomes
One of the key lessons from the US market is the importance of linking price to performance. This requires deeper analytics, long-term monitoring, and structured data gathering. Outcome-based agreements have become more common as stakeholders look for ways to reduce uncertainty in high-cost therapies. For global firms, this means investing in frameworks that capture real-world evidence across the entire patient journey. The ability to track adherence, health improvements, and economic impact helps justify pricing decisions and strengthens payer negotiations.
Strengthening Cross-Stakeholder Collaboration
The US experience shows that collaboration is essential for sustainable value-based pricing. Payers, regulators, clinicians, and manufacturers must work together to define meaningful metrics. Global healthcare firms should mirror this collaborative model by engaging stakeholders early in the pricing process. When all parties agree on evaluation criteria, it becomes easier to create agreements that balance affordability with innovation incentives. This approach also supports better forecasting and reduces friction during market entry.
Using Data and Technology to Drive Transparency
Advanced analytics and digital tools have played a major role in reshaping US pricing practices. Firms can draw on claims data, electronic medical records, and patient-reported outcomes to build stronger value arguments. Predictive modeling can help estimate long-term impact with greater accuracy. For global organizations, adopting similar data-driven capabilities can improve both pricing credibility and operational efficiency. Transparent evidence pathways also foster trust among regulators and healthcare professionals.
Managing Global Variations in Market Expectations
While the US market provides a blueprint, global firms must adapt value-based pricing to local healthcare structures. Each country has distinct reimbursement processes, regulatory environments, and cost sensitivities. The US model highlights the need for tailored pricing tiers that reflect economic differences while maintaining a consistent value foundation. Firms should design modular pricing frameworks that can be localized without undermining core principles. This adaptability supports smoother market access and stronger global positioning.
Preparing for Future Pricing Evolution
The ongoing transformation in US healthcare suggests that value-based pricing will continue to expand. Global firms should be proactive by developing internal capabilities that support long-term sustainability. This includes training teams in health economics, investing in outcome measurement systems, and strengthening regulatory intelligence. Continuous scenario planning will help organizations stay ahead of policy adjustments and evolving payer expectations.
Conclusion
Building a value-based pricing strategy requires more than adjusting cost models. It demands a shift toward measurable outcomes, transparent communication, and collaborative decision-making. Lessons from the US market show how data, stakeholder alignment, and evidence-based frameworks can create pricing systems that support both innovation and accessibility. Global healthcare firms that embrace these insights can navigate complex markets more effectively while delivering meaningful value to patients and health systems.
In May 2025, the US government enacted a sweeping executive order aimed at cutting prescription drug prices by up to 90 percent,1 aligning them with prices in other developed nations via a Most-Favored Nation (MFN) drug pricing model. The policy represents one of the most significant structural reforms in US healthcare in decades, targeting intermediaries such as Pharmacy Benefit Managers (PBM), curbing rebate-driven opacity and promoting transparent, direct-to-consumer pricing models.
This move arrives amid mounting pressure on the healthcare ecosystem. The prescription drug spending in the US has more than doubled – from USD 208 Billion in 2005 to over USD 463 Billion in 2024,2 driven by high-cost specialty drugs, pricing opacity and a fragmented value chain. Drug prices in the US are estimated to be two to three times higher than in countries such as Germany, Canada and the UK.3 Simultaneously, Selling, General and Administrative (SG&A) costs across healthcare have outpaced inflation, straining provider margins and payer reserves.
This article explores the implications of the MFN pricing model and outlines how future-ready healthcare organizations can respond by driving operational agility, digitizing aggressively and re-thinking value delivery.
The 2025 US drug pricing reforms come at a time when the healthcare industry is already transforming, shaped by evolving policies, technological disruption and heightened consumer expectations.
In 2010, drug costs comprised 12 percent of total US healthcare spend. In 2024, that figure exceeded 17 percent.4 The MFN model seeks to arrest this trend but at the cost of business-as-usual for payers.
PBMs are among the most directly impacted by the executive order, with their traditional rebate-based revenue models now under pressure. As regulatory scrutiny intensifies and transparency becomes non-negotiable, PBMs will need to pivot toward more accountable, digitally transparent operations.
Rather than calling for the elimination of PBMs, industry stakeholders such as AHIP have emphasized the need for structural reform. AHIP’s 2024 position5 highlights the importance of transparency and contracting flexibility in enabling PBMs to continue delivering value to employers and consumers.
Health systems will need to respond swiftly to shifts in pharmaceutical procurement and pricing strategies. Departments managing drug acquisition, reimbursement and patient billing will face immediate challenges in aligning budgets and supply chain agreements with the new mandates. Beyond operational re-calibration, there will be implications for patient access, especially for high-cost therapies that may be re-priced or re-classified.
© 2025 Crivva - Hosted by Airy Hosting Managed Website Hosting.
